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ABSTRACT
Background and aims: The effect of metabolic risk
factors on the natural course of gastro-oesophageal reflux
disease (GORD), which remains elusive, was quantified.
Methods: The population included 3669 subjects under-
going repeated upper endoscopy. Data were analysed
using a three-state Markov model to estimate transition
rates (according to the Los Angeles classification)
regarding the natural course of the disease. Individual risk
score together with the kinetic curve was derived by
identifying significant factors responsible for the net force
between progression and regression.
Results: During three consecutive study periods, 12.2,
14.9 and 17.9% of subjects, respectively, progressed from
non-erosive to erosive disease, whereas 42.5, 37.3 and
34.6%, respectively, regressed to the non-erosive stage.
The annual transition rate from non-erosive to class A–B
disease was 0.151 per person year (95% CI 0.136 to
0.165) and from class A–B to C–D was 0.079 per person
year (95% CI 0.063 to 0.094). The regression rate from
class A–B to non-erosive disease was 0.481 per person
year (95% CI 0.425 to 0.536). Class C–D, however,
appeared to be an absorbing state when not properly
treated. Being male (relative risk (RR) 4.31; 95% CI 3.22
to 5.75), smoking (RR 1.20; 95% CI 1.03 to 1.39) or
having metabolic syndrome (RR 1.75; 95% CI 1.29 to
2.38) independently increased the likelihood of progres-
sing from a non-erosive to an erosive stage of disease
and/or lowered the likelihood of disease regression. The
short-term use of acid suppressants (RR 0.54; 95% CI
0.39 to 0.75) raised the likelihood of regression from
erosive to non-erosive disease.
Conclusions: Intraoesophageal damage is a dynamic and
migratory process in which the metabolic syndrome is
associated with accelerated progression to or attenuated
regression from erosive states. These findings have
important implications for the design of effective
prevention and screening strategies.
Gastro-oesophageal reflux disease (GORD) is
becoming increasing prevalent in the population,
paralleling similar rises in the frequency of meta-
bolic disorders, and resulting in the concomitant
growth of an already considerable economic
burden.
1 Although GORD substantially affects
public health, its natural history remains elusive.
Two opposing theories have been proposed to
explain the GORD heterogeneity. The category
theory holds that GORD can be treated as three
distinct entities (non-erosive (NE) reflux disease,
erosive reflux disease and Barrett’s oesophagus
23 )
and arises from the fact that therapeutic responses
differ substantially between erosive and NE disease
stages. The continuum theory suggests that GORD
is a spectrum of diseases with differing severities.
Support derives from the fact that transitions from
NE to erosive disease are observed during endo-
scopic follow-up,
4 and disease severity might
account for observed variations in therapeutic
responses.
5
Several studies have reported that the adverse
effect of obesity on GORD is through mechanical
alterations at the oesophagogastric junction.
6–10
However, since not every obese patient develops
GORD, the pathogenesis must be multifactorial
and cannot be explained by a single physiological
parameter.
11 Therefore, knowledge of GORD’s
natural history and its relationship with metabolic
risk factors is very informative not only to identify
which individuals should undergo endoscopic
screening but also to develop individually tailored
prevention strategies. Unfortunately, it is difficult
to assess GORD’s natural history because of the
paucity of data from large, long-term endoscopic
follow-up studies and the fact that symptoms of
the disease cannot be treated as a surrogate
measure for endoscopy. Even when data are
available, serial observations with irregular inter-
examination intervals render the quantification of
transition between states and the derivation of
kinetic curves that shows how each state evolves
with time hard to assess without using complex
multistate models. Our primary aim was to
quantify the effect of putative factors, particularly
the effect of metabolic risk factors, on the rates of
onset, progression and regression between NE and
erosive disease states.
METHODS
Participants and evaluation
Our study was based on a voluntary health
promotion programme at National Taiwan
University Hospital (NTUH) that used a standard
protocol including a physical examination, blood
chemistries, plain radiography, abdominal ultra-
sonography and endoscopy. Most subjects were
invited to undergo an upper gastrointestinal
endoscopy annually. Such a scheme is confirmed
to be effective for cancer prevention in areas where
the upper gastrointestinal cancers are prevalent.
12–14
The ethics committee at our hospital approved the
study protocol.
We enrolled patients who underwent at least
two endoscopic examinations. Excluded were
those who received proton pump inhibitors (PPIs)
or histamine-2 receptor antagonists (H2RAs) in the
4 months preceding the first endoscopy, those who
underwent gastrectomy and those with malig-
nancy. National Health Insurance in Taiwan
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those who show signs of erosive oesophagitis or peptic ulcer
disease after endoscopy.
15 These medications are not available
over-the-counter in Taiwan. Subjects who received less than 4
months of treatment were defined as short-term users. They
were included in the analysis since a short-course PPI/H2RA
treatment for erosive oesophagitis is the common clinical
practice.
16 Those who required two or more successive courses
of PPI or H2RA treatment were defined as long-term users.
They were excluded because such treatment may strongly affect
GORD’s natural history.
Prior to the examination, a self-administered questionnaire
was used to collect information on demographics, social habits
and medical/medication histories. We defined symptoms of
GORD as the presence of troublesome heartburn, acid
regurgitation or both. Heartburn was defined as a burning
sensation in the retrosternal area and acid regurgitation as the
perception of flow of refluxed gastric contents into the mouth
or hypopharynx. The frequency was once a week or more over
the past 3 months. Self-reported data were confirmed in a face-
to-face interview with an internist.
17 This GORD-specific
approach has been validated in population-scale research.
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Participants were evaluated for metabolic risk factors,
including measurements of body mass index (BMI), waist
circumference, blood pressure, plasma glucose, total cholesterol,
high-density lipoprotein (HDL) cholesterol, triglycerides and
uric acid levels. According to the modified criteria for Asians,
19
metabolic syndrome is the presence of three or more of the
following: waist circumference .90 cm for men or .80 cm for
women, serum triglyceride levels >150 mg/dl, HDL cholesterol
levels ,40 mg/dl, blood pressure >130/85 mm Hg and serum
glucose levels >110 mg/dl. Those receiving antidiabetic or
antihypertensive therapy were assumed to have high fasting
glucose levels or high blood pressure (details have been described
elsewhere).
20
After the evaluation of metabolic risk factors, subjects
underwent endoscopy. Erosive oesophagitis was scored using
the Los Angeles (LA) classification system with standard
comparator photos.
21 The original LA classification for erosive
oesophagitis consists of four classes but we combined these into
two categories (classes A–B and C–D) to reduce interobserver
variation
22 and increase statistical power. The overall k changed
from 0.45 to 0.65, suggesting good consistency.
23
Three-state Markov model
We modelled GORD’s natural history as a three-state Markov
process by defining state 1 as NE disease, state 2 as LA class A–B
oesophagitis and state 3 as class C–D oesophagitis (fig 1).
Transitions between serial states were quantified by two
instantaneous progression rates from state 1 to 2 (l1) and from
state 2 to 3 (l3), and two instantaneous regression rates from
state 2 to 1 (l2) and state 3 to 2 (l4).
Cumulative risk for each transition was computed by
transition probabilities that were a function of transition rates
l1–l4 and follow-up time by using the method of Chen et al.
24
The evolution of these cumulative risk curves corresponding to
state-to-state transitions of GORD’s natural course with
follow-up time are called kinetic curves. For subjects free of
erosive disease at baseline, kinetic curves showed the evolution
of cumulative risk for developing class A–B and class C–D
oesophagitis and probability of remaining in the NE disease
state. For subjects with class A–B disease at baseline, kinetic
curves showed the evolution of cumulative risk for developing
class C–D, remaining in class A–B and regressing to the NE
disease state.
Statistical analysis
Time intervals between endoscopic examinations were recorded
to build up a continuous-time Markov process for the three-
state model. We estimated the transition rates labelled in fig 1
and their 95% CIs based on the total likelihood, a product of
transition probabilities from a series of endoscopic examinations
in all subjects. Statistical analyses for this model have been
described in several papers.
24–28 As time intervals between
assessments are irregular and vary from individual to individual,
a multistate model is adopted to tackle this technical problem
with the incorporation of different time intervals into transition
probabilities, which is elaborated in Appendix 1.
We presented the model parameters derived from the
complete data set of subjects. To test the predictive validity of
the current model, we also performed cross-validation by
splitting data into 2/3 for deriving the model and 1/3 for
validation of the model. The observed transition histories in the
validated data set were compared with the predicted ones that
were computed by the application of parameters trained from
the derived data set.
As we are interested in the effect of metabolic risk factors on
transition rates, a univariate regression analysis was therefore
done to assess the effect of each component on transition rates.
The exponential Markov regression form was adapted to
estimate relative risk (RR), which is done by taking exponentials
of the regression coefficients of the Markov regression. Besides
the metabolic profile, factors considered in the regression
included basic demographic information, lifestyle factors,
symptoms of reflux and the use of acid suppressants following
screening. It should be noted that each predictor in the same
individual may vary from time to time and was repeatedly
evaluated along with each endoscopic screening. They are
treated as time-varying covariates, which means that their
contributions to progression and regression of GORD may
depend on the status they had at the time preceding the next
transition during a given epoch. Thus, the net force of dynamic
change of each covariate contributing to progression and
regression is worthy of investigation.
Take smoking status (smoking, X=1; no smoking, X=0), for
example. An individual at time t0 was a current smoker (X=1),
he developed A–B during time interval (t1–t0), quit smoking,
was treated as non-smoking (X=0), at time t1, regressed to NE
during the time interval (t2–t1), and stayed as NE without
smoking until time t3. Thus, as smoking status changed with
time, its effect in each epoch makes different contributions to
disease progression and regression in the same individual. The
net force of smoking on the state-to-state transitions can be
considered in this manner to aggregate each individual change
into a population-average net effect expressed by the difference
of regression coefficients between progression and regression.
Figure 1 Three-state Markov model of the natural history of gastro-
oesophageal reflux disease. The transition rates, l1–l4, are parameters
in the model and will be estimated.
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associated with progression on the grounds of indication and
regression probably causally related through treatment.
Hypothesis testing for such net force for each risk factor
mentioned above is performed as follows. The transition rate
function is first developed:
lj(t)=l0j(t)exp(bjX(t)), for j=1,2
where l01 and l02 are baseline progression and regression rates,
b1 and b2 are the corresponding regression coefficients, and X(t)
is the indicator variable concerned with the presence of risk
factors at time t prior to the next transition. The null hypothesis
for an attributed lack of effect due to a risk factor is defined as
b1–b2 (net effect)=0. The alternative hypothesis was set as b1–
b2?0, where b1–b2.0 indicates a detrimental effect and b1–
b2,0 indicates a protection. By using the estimated variance–
covariance matrix, the significance of a risk factor was
determined using the Wald test statistic.
To build a multivariate model, we used forward selection to
evaluate the additive effects of risk factors. The presence of
metabolic syndrome, and its individual components, were added
one by one into the model. The final model was selected based
on the log-likelihood ratio test.
29 Using the set of risk factors
that were significant in the final model, we created a predicted
risk score based on regression coefficients estimated from the
model and the assigned time-invariant and time-varying factors.
Following the above notation of b1 and b2, the predicted risk
score at time t (S(t)) for each set of risk factors is expressed by:
where Xj(t) is a set of significant factors and q is the number of
significant factors. Risk stratification according to this predicted
risk score yielded a series of different kinetic curves with
different shapes, showing heterogeneous natural courses of
disease. Analysis was done using an SAS/IML procedure
(version 9.1; SAS Institute Inc., Cary, North Carolina, USA).
All p values were two sided; p,0.05 indicated significance.
RESULTS
Descriptive findings
Between June 2003 and December 2006, 19 812 subjects
underwent screening upper endoscopy at NTUH. Of these,
3669 had at least two examinations and comprised our study
group (table 1). Mean age (SD) was 56.3 (10.5) years; mean BMI
was 24.1 (3) kg/m
2. GORD symptoms were reported in 11.3%.
The prevalence rate (16.4%) of erosive oesophagitis among these
3669 subjects was similar to that (15.7%) obtained from the
whole population (n=19 812) in the previous study.
30 This may
suggest that we did not have findings on the first endoscopy
that warranted more frequent surveillance for these subjects
with repeated endoscopy. Stratified by their endoscopic find-
ings, 10.3% of NE, 15.5% of A–B and 35.3% of C–D groups had
GORD symptoms. The average duration of short-term PPI or
H2RA treatment was 2.1 (0.8) months. Thirty patients (0.15%)
were excluded for being long-term PPI or H2RA users. Barrett’s
oesophagus was too rare (0.06%) to be included.
30 As only 0.35%
had chronic renal insufficiency (serum creatinine concentration
>2 mg/dl), this was also excluded.
Transition rates between states in GORD’s natural history
Subjects underwent up to four endoscopies creating three
epochs (baseline endoscopy to endoscopy 2, endoscopy 2 to 3,
and endoscopy 3 to 4). The mean duration of epochs 1, 2 and 3
(in days) was 528 (210), 392 (108) and 352 (60). Table 2 shows
aggregate numbers of observed transitions between states.
There were 5145 transitions, including 3669 in epoch 1, 1401
in epoch 2, and 336 in epoch 3. Observed rates of transition
from NE to erosive oesophagitis were 12.2% (95% CI 8.9% to
15.5%), 14.9% (95% CI 9% to 20.8%) and 17.9% (95% CI 13.2%
to 22.6%). The risk of progressing from class A–B to class C–D
Table 1 Baseline characteristics of the 3669 study subjects
Characteristic No. of subjects (%)
Male 2483 (67.7)
Smoker 416 (11.3)
Drinks alcohol (at least once per week) 2219 (60.5)
Chronic illnesses
Cardiac 47 (1.3)
Pulmonary 92 (2.6)
Hepatic 501 (13.7)
Peptic ulcer 648 (17.7)
Cholesterol >200 mg/dl 314 (8.6)
Hyperuricaemia* and/or history of gout 283 (7.7)
Metabolic syndrome 498 (13.6)
Enlarged waist circumference 1239 (33.8)
Hypertension or blood pressure >130/85 mm Hg 559 (15.2)
Diabetes or fasting glucose >110 mg/dl 198 (5.4)
HDL-C ,40 mg/dl 1678 (45.7)
Triglycerides >150 mg/dl 908 (24.7)
Exercise, number of times per week
>5 1013 (27.6)
3–4 1585 (43.2)
(2 1071 (29.2)
Sleep quality
Good 1600 (43.6)
Fair 1564 (42.6)
Poor 505 (13.8)
Symptoms of GORD 413 (11.3)
Short-term use of PPI or H2RA 587 (11.4){
GORD, gastro-oesophageal reflux disease; H2RA, histamine-2 receptor antagonist;
HDL-C, high-density lipoprotein cholesterol; PPI, proton pump inhibitor.
*Serum uric acid concentration .7.5 mg/dl.
{From 5145 transition periods.
Table 2 Aggregate counts of transitions between states during the
three study epochs
Epochs
No. of subjects (%)
NE Class A–B Class C–D
Baseline Endoscopy 2 (n=3669)
NE (n=3066) 2693 (87.8) 350 (11.4) 23 (0.8)
Class A–B (n=586) 249 (42.5) 304 (51.9) 33 (5.6)
Class C–D (n=17) 0 (0) 0 (0) 17 (100)
Endoscopy 2 Endoscopy 3 (n=1140)
NE (n=930) 791 (85.1) 136 (14.6) 3 (0.3)
Class A–B (n=198) 74 (37.3) 109 (55.1) 15 (7.6)
Class C–D (n=12) 0 (0) 0 (0) 12 (100)
Endoscopy 3 Endoscopy 4 (n=336)
NE (n=252) 207 (82.1) 45 (17.9) 0 (0)
Class A–B (n=78) 27 (34.6) 39 (50) 12 (15.4)
Class C–D (n=6) 0 (0) 0 (0) 6 (100)
NE, non-erosive state.
Oesophageal disease
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epoch 1 to 15.4% (95% CI 7.4% to 23.4%) in epoch 3; the
probability of regression from class A–B to NE decreased from
42.5% (95% CI 38.5% to 46.5%) in epoch 1 to 34.6% (95% CI
24.8% to 44.4%) in epoch 3. However, no statistically significant
increase in progression or decrease in regression across epochs
was noted (p.0.05). Because no class C–D subjects showed
regression to class A–B or NE, the annual regression rate from
C–D to A–B (ie, l4) was set to zero.
Annual progression rates from NE to A–B (ie, l1) and from A–
B to C–D (ie, l3) were 0.151 (95% CI 0.136 to 0.165) and 0.079
(95% CI 0.063 to 0.094) per person year, respectively, and the
regression rate from A–B to NE (ie, l2) was 0.481 (95% CI 0.425
to 0.536) per person year. The corresponding figures were 0.139
(95% CI 0.126 to 0.152), 0.084 (95% CI 0.066 to 0.101) and 0.346
(95% CI 0.294 to 0.398) when we excluded the transition
histories of being administered with short-term PPI or H2RA
treatment preceding the next transition.
Kinetic curves
Model fitting was assessed by comparing predicted with
observed transitions using x
2; the lack of a significant difference
indicated a good fit for the model (p=0.415). The observed
transition histories were still compatible with the predicted
values using the cross-validation method (p=0.876). Figure 2A
shows the cumulative risk of developing class A–B (middle
curve) and class C–D oesophagitis (bottom curve) and the
probability of staying in the NE disease state (upper curve) for
subjects free of erosive disease at baseline. After a 10-year
follow-up, 68% of patients have NE disease, 19% class A–B, and
13% class C–D. Since disease regression is common, only 8% of
patients would stay in the NE state throughout the follow-up
period without any transition histories. Figure 2B shows the
cumulative risk of progressing to C–D, of remaining in A–B and
of regressing to NE for subjects with A–B at baseline,
respectively. Of these, 60% would undergo regression to NE
within 10 years, 17% would remain as A–B, and 23% would
progress to C–D.
Effects of risk factors on GORD’s natural course
Univariate analysis
Table 3 shows the results when we introduced covariates one by
one into our model. We only evaluated effects on transitions
between NE and A–B because there were too few transitions
from A–B to C–D to allow stable parameter estimation.
Being male (RR=2.36) and having a BMI >27 kg/m
2
(RR=1.28) both raised the likelihood of progressing from NE
to erosive disease and lowered the likelihood of regression from
erosive to NE disease (RR=0.55 and 0.70). Smokers and heavy
drinkers had a significant risk of erosive disease (RR=2.27 and
1.32). Subjects with metabolic risk factors, including hyperch-
olesterolaemia, hyperuricaemia, enlarged waist circumference,
hypertension, low HDL cholesterol level, hypertriglycaemia and
metabolic syndrome, were more likely to progress from NE to
erosive disease and/or less likely to regress from erosive to NE
states. Short-term PPI or H2RA use increased the likelihood of
regression from erosive to NE states (RR=2.83). GORD
symptoms increased the risk of erosive disease (net RR=1.64).
Multivariate analysis
We used forward selection to evaluate the additive effects of
covariates on disease onset and regression. The initial model
included only gender (the most significant factor in univariate
analysis). We then added variables until they stopped adding
significantly to the model. The final model included gender,
smoking, metabolic syndrome and short-term PPI or H2RA
usage (see table 4 for resulting risk estimates).
The clinical weight each risk factor contributes to (the net
effect of regression coefficients) was 1.46 (natural logarithm of
4.31) for male gender, 0.18 for smoking, 0.56 for metabolic
syndrome and 20.61 for short-term PPI or H2RA. The predicted
risk score at time t based on the clinical weight together with
risk factor was:
Risk score=(1.466male)+(0.186smoking)+(0.566metabolic syndro-
me)2(0.616short-term use of PPI or H2RA)
Figure 2 (A) The kinetic curves (cumulative probabilities, see Appendix 2) of transition from non-erosive to class A–B or class C–D disease, and of
remaining in the non-erosive state. (B) The kinetic curves (cumulative probabilities) of transition from class A–B to class C–D disease, of remaining in
the class A–B disease state, and of regression from class A–B to the non-erosive state.
Oesophageal disease
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table 4.
Kinetic curves can be stratified by classifying predicted risk
score into four categories, as shown in fig 3A–D. A female with
reflux, for example, who does not smoke or have metabolic
syndrome but received short-term PPI treatment (total risk
score of 0+0+020.61=20.61), would have the lowest prob-
ability of progressing to erosive disease (fig 3A, low risk group).
An untreated male smoker with metabolic syndrome (total risk
score of 1.46+0.18+0.5620=2.2) would have the highest
probability of progressing from NE to erosive disease (fig 3D,
high risk group). The higher the risk score, the higher the
probability of developing erosive oesophagitis.
DISCUSSION
We quantified the natural history of GORD by fitting a
large longitudinal follow-up database of patients undergoing
endoscopy. The step-by-step transitions are a solid demonstra-
tion of GORD’s dynamic nature. The predicted risk score may
enable clinicians to develop individually tailored preventive
strategies.
In addition to cross-validation, several studies support our
model’s credibility on external predictive validity. Among
patients with NE reflux disease, 5/33 (15%) developed erosive
changes within 6 months
31; 16 of 18 (89%) became erosive 10
years later.
32 A large database of 2306 GORD patients showed
that oesophageal mucosa over 7.6 months was unchanged in
67% of patients (our model predicted 67%), improved in 21%
(predicted, 27%) and worsened in 11% (predicted, 6%).
33 Among
3894 GORD patients followed for 2 years, 25% with NE reflux
disease progressed to A–B (predicted, 18%) and 0.6% progressed
to C–D (predicted, 1.5%); 37% of those with A–B remained A–B
(predicted, 39%) and 61% regressed to NE (predicted, 51%).
4
Five years later, 72% of those with NE reflux disease at baseline
Table 3 Relative risk of transition and corresponding 95% CIs by factors from the univariate three-state Markov model
Variables*
RR (95% CI){
NERclass A–B Class A–BRNE Net effect
Age >65 years 1.19 (0.95 to 1.48) 1.02 (0.78 to 1.34) 1.17 (0.91 to 1.50)
Male 2.36 (1.79 to 3.13){ 0.55 (0.40 to 0.74){ 4.33 (3.30 to 5.66){
Body mass index >27 kg/m
2 1.28 (1.01 to 1.65){ 0.70 (0.52 to 0.96){ 1.81 (1.36 to 2.41){
Smoker 2.27 (1.68 to 3.06){ 1.38 (0.96 to 1.97) 1.65 (1.24 to 2.18){
Alcohol use 1.32 (1.08 to 1.62){ 0.99 (0.78 to 1.26) 1.34 (1.07 to 1.69){
Chronic disease
Cardiac 0.28 (0.07 to 1.16) 1.19 (0.59 to 2.39) 0.23 (0.06 to 1.02)
Pulmonary 0.98 (0.58 to 1.65) 0.53 (0.19 to 1.45) 1.86 (0.72 to 4.80)
Hepatic 1.01 (0.76 to 1.34) 1.09 (0.79 to 1.54) 0.92 (0.67 to 1.26)
Peptic ulcer disease 1.17 (0.92 to 1.49) 0.88 (0.66 to 1.17) 1.33 (1.02 to 1.75){
Cholesterol >200 mg/dl 0.86 (0.63 to 1.19) 0.52 (0.34 to 0.79){ 1.66 (1.08 to 2.55){
Hyperuricaemia and/or history of gout 1.46 (1.06 to 1.99){ 0.90 (0.61 to 1.34) 1.61 (1.12 to 2.33){
Metabolic syndrome 1.42 (1.11 to 1.80){ 0.76 (0.55 to 0.97){ 1.87 (1.40 to 2.51){
Enlarged waist circumference 1.02 (0.84 to 1.25) 0.78 (0.61 to 0.99){ 1.31 (1.04 to 1.65){
Hypertension or blood pressure >130/85 mm Hg 1.32 (1.04 to 1.68){ 0.87 (0.64 to 1.17) 1.53 (1.15 to 2.04){
Diabetes or fasting glucose >110 mg/dl 1.00 (0.68 to 1.48) 0.68 (0.42 to 1.09) 1.48 (0.91 to 2.41)
HDL-C ,40 mg/dl 1.39 (1.15 to 1.68){ 1.00 (0.79 to 1.26) 1.39 (1.12 to 1.73){
Triglycerides >150 mg/dl 1.17 (0.95 to 1.45) 0.71 (0.55 to 0.91){ 1.66 (1.30 to 2.12){
Exercise frequency 0.94 (0.76 to 1.17) 1.11 (0.87 to 1.45) 0.84 (0.67 to 1.07)
Sleep quality 1.03 (0.77 to 1.38) 1.12 (0.81 to 1.54) 0.92 (0.68 to 1.25)
Symptoms of GORD 1.23 (0.93 to 1.63) 0.76 (0.54 to 1.05) 1.64 (1.18 to 2.27){
Short-term use of PPI or H2RA 1.31 (0.86 to 1.97) 2.83 (2.14 to 3.71){ 0.46 (0.33 to 0.65){
*Factors were dichotomsed (no/yes) as follows: age >65 years, male, body mass index >27 kg/m
2, smoker, alcohol consumed > once per week, metabolic syndrome, exercise
more than twice per week, poor sleep quality, symptoms of GORD and use of short-term PPI or H2RA. The ‘‘no’’ group constitutes the baseline comparator.
{The RR for evaluating the role of each factor was arrived at by taking the exponential of the regression coefficient (b) of the Markov regression—that is, exp(b1) for progression,
exp(b2) for regression and exp(b1–b2) for the net effect.
{p,0.05.
GORD, gastro-oesophageal reflux disease; HDL-C, high-density lipoprotein cholesterol; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.
Table 4 Relative risk of transition and corresponding 95% CIs from the multivariate three-state Markov
model
Variables*
RR (95%CI){
NERclass A–B Class A–BRNE Net effect
Male 2.36 (1.73 to 2.97){ 0.53 (0.40 to 0.74){ 4.31 (3.22 to 5.75){
Smoker 1.77 (1.32 to 2.36){ 1.48 (0.98 to 2.15) 1.20 (1.03 to 1.39){
Metabolic syndrome 1.29 (1.18 to 1.42){ 0.74 (0.53 to 0.98){ 1.75 (1.29 to 2.38){
Short-term use of PPI or H2RA 1.73 (0.92 to 2.77) 3.19 (2.32 to 4.44){ 0.54 (0.39 to 0.75){
*Factors were dichotomised (no/yes) as follows: male, smoker, metabolic syndrome and use of short-term use of PPI or H2RA. The
‘‘no’’ group constitutes the baseline comparator.
{The RR for evaluating the role of each factor was arrived at by taking the exponential of the regression coefficient (b) of the
Markov regression—that is, exp(b1) for progression, exp(b2) for regression and exp(b1–b2) for the net effect.
{p ,0.05.
H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor.
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(predicted, 20%) and 6% progressed to C–D or Barrett’s
oesophagus (predicted, 6%). For patients with class A–B at
baseline, 57% regressed to NE (predicted, 63%), 31% stayed A–B
(predicted, 21%) and 12% became C–D disease or Barrett’s
oesophagus (predicted, 16%).
34
A plausible link can be established between category and
continuum theories. The most significant factor affecting
vulnerability to erosive oesophagitis is gender. Hence, a slim
female who does not smoke or drink alcohol may remain in the
NE state for a long time with little chance of developing erosive
disease. An obese male, in contrast, who smokes, drinks heavily
and has metabolic syndrome (again a typical picture) would
probably progress to erosive disease. The probability of changes
in disease status being detected at endoscopy would also
increase. Thus, different combinations of risk factors lead to
different severities of intraoesophageal damage and the disease
appears as a continuum upon endoscopic inspection.
The pathogenesis of reflux symptoms is complicated and
cannotbeexplainedsolelybyintraoesophagealdamage.Enhanced
peripheraland centralneuralperceptions of stimuli may becrucial
in symptom generation.
35 As the above illustrates, demographic
and endoscopic findings can vary markedly in symptomatic
patients and may explain why GORD seems categorical under a
symptom-oriented approach. Treating cases of reflux as catego-
rical entities accordingto the mechanisms of symptom generation
is worthwhile; however, the value of identifying risk factors and
protecting the oesophageal mucosa from irreversible damage
cannot be overemphasised. Since spontaneous regression is still
possible in patients with low-grade erosive disease without
pharmacological treatment, evaluation of individual risk at this
stage would give patients opportunities to modify their behaviour
(weight reduction, giving up smoking) and enable clinicians to
select patients most likely to develop irreversible changes for
endoscopic screening and offer them early pharmacological
treatment. This argument has been supported by our findings.
Figure 3 The kinetic curves (cumulative probabilities) of transition from non-erosive to class A–B or class C–D disease, and of remaining in the non-
erosive disease state, stratified by individual risk score. A to D illustrate, respectively, the cumulative probability of transition between the above states
for those with a risk score of ,0, of between 0 and 1, of between 1 and 2, and of .2.
Oesophageal disease
Gut 2009;58:174–181. doi:10.1136/gut.2008.162305 179After removing the effect of short-term treatment, the regression
rate has been attenuated from 0.481 to 0.346. This suggests the
short-term treatment effect accounts for 27% (120.35/0.48) and
other significant risk factors are responsible for 73%. The
possibility of disease regression, making allowance for short-term
treatmenteffect,remainedandmayberelatedtothemodification
of other risk factors.
Obesity significantly increased the risk of GORD symptoms,
erosive oesophagitis, Barrett’s oesophagus and oesophageal
adenocarcinoma.
6–8 However, obesity cannot be the sole reason.
Hypertension was found, after adjusting for BMI, to be
associated with erosive oesophagitis.
36 In a Japanese population,
male sex, obesity, hyperglycaemia and hypertension were
independent risk factors for erosive oesophagitis.
37
Investigating a database of a Korean population, the presence
of metabolic syndrome and a higher visceral adipose tissue area
were risk factors.
38 Consistent with the above, we found an
association between several metabolic risk factors and acceler-
ated progression to or attenuated regression from erosive
disease, which suggests a potential benefit of treating metabolic
disorders in GORD patients. The recommendation to abstain
from smoking and alcohol is justified.
Our results are credible for several reasons. First, we had
numerous cases of NE and were able to assess progression to
erosive disease. The simultaneous evaluation of symptomatic and
asymptomaticsubjectsalsoenabledustoobservetheentiredisease
spectrum. Secondly, all our endoscopists completed the same
training programme using a standardised rating protocol. This
substantially reduced heterogeneity amongst observers and
strengthened our ability to model natural history. Thirdly, we
found no spontaneous regressions from high-grade erosive states,
w h i c hc o n f l i c t sw i t hf i n d i n g st h a t4 2 %o fp a t i e n t sw i t hc l a s sC – D
diseaseregresstoA–Band50%toNEdiseasewithin2years.
4These
latter results were obtained from symptomatic patients with
GORD who were participating in a therapeutic trial and are
potentially confounded by pharmacological effects. The fact that
most of our participants remained asymptomatic, even in high-
grade erosive states, lowered their incentive to seek treatment and
allowedustoassesstheuninterruptednaturalhistoryofthedisease.
Because progression of GORD is orderly, the Markov
approach was appropriate for modelling. However, our target
group tended to reflect the general population, so there were
few transitions from low- to high-grade oesophagitis and we
were unable to investigate the effects of covariates on this stage.
Secondly, information about H pylori infection was not
available. For subjects with antrum-predominant gastritis, H
pylori may increase gastric acid secretion and thus increase the
risk of GORD.
39 40 This is supported by our finding that peptic
ulcer disease (mostly duodenal ulcer) at baseline was associated
with a higher risk of progression to an erosive state. However,
the effect of H pylori eradication on GORD should be
investigated. Finally, a short course of acid-suppressing treat-
ment is common among patients with minor erosive disease,
and considering this factor in the Markov model may improve
its ability to predict disease progression.
16 However, the
exclusion of long-term users of PPIs or H2RAs may limit the
generalisability of the model to patients with earlier onset
disease or more severe disease. The evaluation of a large and
longitudinal database is warranted in order to update our
parameter estimates and extend our model to include patients
who require long-term treatment with acid-suppressing medica-
tion and who are diagnosed with Barrett’s oesophagus.
Our findings suggest that intraoesophageal damage develops
as a dynamic process over time. Risk factors in susceptible
individuals modulate the likelihood of state-to-state transitions,
resulting (upon endoscopy) in the appearance of a continuous
spectrum of disease. GORD can therefore be staged with respect
to the extent of progression, as with many other chronic
diseases. The translation of the quantified knowledge of
GORD’s natural history into predicted risk score together with
the kinetic curve will be vital for developing individually
tailored prevention and screening programmes, to identify
candidates for potential interventions, and to determine optimal
timing of proposed interventions.
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APPENDIX 1
Model specification and the likelihood function for data on
endoscopic examination
The transition rates in our three-state model can be expressed in an intensity matrix as
follows:
where states 1, 2 and 3 represent states NE, LA class A–B and LA class C–D,
respectively. The four transition parameters of l1–l4 have been defined in the text
and fig 1. Using the Kolmogorov equation,
25 the corresponding transition probabilities
can be expressed as follows:
where Pij(t)=Pr{X(tl)=j|X(tl–1)=i} is a function of l1–l4,0,tl–1 , tl; i, j=1,
2, 3.
Each individual has his/her own history of endoscopic examination. The likelihood
function is established based on the transition probabilities with the use of the data on
the history of examinations, in order to estimate the transition parameters l1–l4.
Such a type of data could be, for example, a man of age 53 years who had undergone
repeated endoscopic examinations with the results as follows: NE with smoking on 12
September 2003, class A–B non-smoking on 27 September 2004, NE on 22 July 2005,
and NE, again, on 1 June 2006. According to the ‘‘lack memory’’ property of a Markov
process, this personal history can be decomposed into three epochs according to the
consecutive four endoscopic examinations: (NERclass A–B, 1.04 years| smoking on
12 September), (class A–BRNE, 0.82 years| non-smoking on 27 September),
(NERNE, 0.86 years| still non-smoking on 22 July), as shown for the study group as
a whole in table 2. The likelihood of an individual following this history is P12(1.04|
smoking)6 P21(0.82| non-smoking)6 P11(0.86| non-smoking). Note that irregular
times are specified for different individuals. To generalise, if n individuals are assessed
at times t0, t1, t2 and t3, creating three epochs (t1–t0), (t2–t1) and (t3–t2), the total
likelihood function for all individuals can be written as:
where the nijl denotes the number of individuals who are in state i at time tl–1 and in
state j at time tl. The maximum likelihood estimates of the transition rates can be
obtained using the Newton–Raphson procedure.
APPENDIX 2
Kinetic curves based on the estimated transition rates
Given the estimated annual progression rates from NE to class A–B oesophagitis and
from A–B to class C–D oesophagitis of 0.151 (l1) and 0.079 (l3) per person year,
respectively, and the regression rate from class A–B to NE and from C–D to class A–B
of 0.481 (l2) per person year and 0 (l4), respectively, the transition rate matrix can be
expressed as follows:
The cumulative risk (probability) over time can be calculated using an SAS/IML
procedure.
26 For example, the first year cumulative risk is demonstrated as follows:
where the upper and middle rows indicate the first year cumulative risks depicted in
the kinetic curve 2A and 2B, respectively.
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